SULFAMETHOXAZOLE

Myeloma

Monash UniversitySmall moleculePhase 3Active

BB

71/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 62/ 100
Competitive Position: 89/ 100

Competitive context

16 Active assets in the Myeloma cohort.

Asset / Sponsor	Phase	Rating
Trimethoprim Monash University	Phase 3	BB
Lipitor Fred Hutchinson Cancer Center	Phase 2	BB
HUMAN IMMUNOGLOBULINS Monash University	Phase 2/3	BB
Arestin M.D. Anderson Cancer Center	Phase 2	B
Campath Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2	B

View all 43 →

Same molecule, other indications

SULFAMETHOXAZOLE is also rated in:

infectious diseaseDormant

A

Indicative ·

81 / 100

methicillin-resistant staphylococcus aureus infectious diseaseDormant

BBB

Indicative ·

75 / 100

PharmacokineticsDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.